Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127621 | 0.90 | ABL1 (0.63) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7128929 | 0.90 | RAB9A (0.67) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7130345 | 0.89 | MEN1 (0.73) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL19435568 | 0.86 | RAB9A (0.61) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7125386 | 0.86 | RAB9A (0.59) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7128794 | 0.86 | MEN1 (0.69) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7120002 | 0.84 | RAB9A (0.66) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7125926 | 0.83 | MEN1 (0.64) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7125353 | 0.83 | RAB9A (0.59) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7130746 | 0.82 | RAB9A (0.69) | MAPTMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134859-A1 | PPAR-gamma modulator | SANKYO COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1277729-A1 | PPAR (GAMMA) MODULATORS | Sankyo Company, Limited (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134859-A1 | PPAR-gamma modulator | PPARG, PPARA, PPARD | MAPT 4391/4885MEN1 4865/4885KMT2A 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.